Mirimus is guided by the leadership of medical specialists, senior scientists, and experienced managers, all of whom understand the unique demands and privileges of working to improve the health of patients. We are continually working to improve the range, accuracy, and convenience of our testing services to empower healthcare professionals and patients to make the best decisions.
In 2020, when COVID-19 hit New York City and it became the epicenter of the pandemic, Mirimus committed its resources to support the fight against COVID-19 and developed a pioneering high-volume saliva-based COVID-19 PCR testing approach called SalivaClear®, performing 4 million tests and servicing hundreds of schools, businesses, and government organizations across the country. SalivaClear won the XPRIZE in 2021, the world’s leading competition to solve humanity’s grand challenges.
Test your population in pools of up to 8 people at regular frequency to detect the presence of infection.
A detected positive pool is tested in smaller pools of 2 samples to isolate the infection of two people.
A positive pool of 2 samples are reflex tested as 2 diagnostic tests to identify the infected individual.
We have been using lessons from the COVID-19 response to address another biological threat: monkeypox. By leveraging our cutting-edge technology and uniquely skilled personnel, Mirimus was able to launch its monkeypox laboratory developed test (LDT) shortly after the World Health Organization declared monkeypox to be a global health emergency. The test is a highly sensitive and specific PCR assay with the ability to detect very low concentrations of the virus. Secure online results will be available within only 24 hours of the lab receiving specimens. Testing is critical to identify the extent of an outbreak, contain it, and to ensure patients can get access to treatment.
